A phase I trial of LX-9211 for the treatment of neuropathic pain
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs LX 9211 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man
- 01 Aug 2017 According to a Lexicon Pharmaceuticals media release, this trial is anticipated to begin in second half 2017.
- 02 May 2017 The Company expects to file an IND for LX9211 in neuropathic pain in mid-2017, according to a Lexicon Pharmaceuticals media release.
- 08 Mar 2017 New trial record